What does the evidence say about Olive Leaf Metabolic Health Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Olive Leaf Metabolic Health Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Introduction Menopause marks the end of a woman's reproductive cycle and is associated with a decline in estrogen levels. [Lasfar A (2025); evidence level 2] - This hormonal shift accelerates systemic aging processes, affecting metabolic regulation, cardiovascular risk, and connective tissue integrity. [Lasfar A (2025); evidence level 2] - Results Elastin levels significantly increased in the placebo group while they remained stable in the OLE group [-6.3 [-12.0; -0.05], p = 0.033], but not after correction for multiple testing ( p adj = 0.0825). [Lasfar A (2025); evidence level 2] - Major risk factors include hypercholesterolemia, hypertension, diabetes, infections, and smoking [,]. [Morvaridzadeh Mojgan (2025); evidence level 3] - Emerging evidence highlights a bidirectional relationship between the gut microbiota and dietary polyphenols, particularly in the modulation of inflammation and lipid metabolism; two central processes in atherosclerosis [,]. [Morvaridzadeh Mojgan (2025); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.